Plain-English translation of NCT07266545 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Researchers want to understand whether specific changes in your cells—called RNA editing—can predict how well an antidepressant will work for you. You'll take one of two medications ( or bupropion) for 8 weeks, and the study team will collect blood samples to look for these cellular changes. This research could help doctors choose the right medication faster for people with depression.
Right now, doctors often have to try different antidepressants through trial and error to find what works. This study aims to find a blood test that could predict which medication will help you before you spend weeks on the wrong one.
You likely qualify if…
You likely don't qualify if…
You'll start taking one of two antidepressant medications daily for 8 weeks, with the dose gradually increased in the first week. You'll come back for regular visits so the study team can check how you're doing and draw blood samples to look for those cellular changes. If your depression hasn't improved enough after 8 weeks, you'll enter a second 8-week phase where the treatment may be adjusted or combined with another medication.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
Mayo Clinic
Enrollment target
~120 participants
Started
February 2026
Primary completion
December 2028
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Scott E. Feeder
Mayo Clinic
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.